Florian Krieger
Moderation: Petra Schultheiß-Reimann
The use of artificial intelligence (AI) has developed into a central technological and scientific approach in preclinical drug research. By analysing high-dimensional biological and chemical datasets, AI methods enable significant acceleration and greater precision in the early stages of development. A wide range of AI-based approaches help to capture complex molecular relationships and support experimental decision-making processes based on data. The increasing integration and improvement of multimodal data sources, together with advances in AI approaches, will continue to transform preclinical research.
Zoom link to the lecture: https://us06web.zoom.us/j/85944698883?pwd=ekQRb3a3rqavoVkM6ZHR8VnVY946MQ.1
There will be a five-minute start-up presentation before the lecture. Dr. Marcel Hövels from Sweethoven Biotech (sweethoven-biotech.com) will present the development of a sweet dietary fibre as a prebiotic and low-glycaemic sugar substitute.
